GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Cash per Share

EDSA (Edesa Biotech) Cash per Share : $0.45 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Edesa Biotech's Cash per Share for the quarter that ended in Dec. 2024 was $0.45.

Edesa Biotech Cash per Share Historical Data

The historical data trend for Edesa Biotech's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Cash per Share Chart

Edesa Biotech Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.25 4.13 2.98 1.74 0.32

Edesa Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 0.87 0.63 0.32 0.45

Edesa Biotech Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Edesa Biotech's Cash per Share for the fiscal year that ended in Sep. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.037/3.25
=0.32

Edesa Biotech's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.564/3.47
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edesa Biotech  (NAS:EDSA) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Edesa Biotech Cash per Share Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Cash per Share
Comparable Companies
AFMD SABS HCWB ATHA OCEA NRXS ABVC MEIP NEUP SPRB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
100 Spy Court, Markham, ON, CAN, L3R 5H6
Website
https://www.edesabiotech.com
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Executives
Pardeep Nijhawan director, 10 percent owner, officer: Chief Executive Officer C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Stephen Lemieux officer: Chief Financial Officer 100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha director 100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall director 100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter director, 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks officer: President C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes director, officer: President, CEO, & Director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson director 3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp 10 percent owner C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli director C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc. 10 percent owner 141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse director C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041